PDCD1 and breast cancer: When Ab-1 and Ab-2 anti-TNFR2 antibodies were combined with nivolumab (anti-PD-1) in a mouse model of MDA-MB-231-established BC, there was a notable increase in CD4+ T cells and CD8+ T cells [313].